Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 32.14M | 29.43M | 18.51M | 12.40M | 8.40M | 5.43M |
Gross Profit | 27.51M | 25.33M | 15.91M | 10.14M | 7.21M | 3.24M |
EBITDA | -22.02M | -36.16M | -58.30M | -46.76M | -23.57M | -25.32M |
Net Income | -27.21M | -33.23M | -59.04M | -47.19M | -28.84M | -31.83M |
Balance Sheet | ||||||
Total Assets | 28.63M | 23.97M | 25.73M | 22.00M | 37.84M | 252.01M |
Cash, Cash Equivalents and Short-Term Investments | 13.00M | 8.53M | 11.78M | 9.41M | 30.30M | 1.33M |
Total Debt | 33.12M | 23.63M | 1.59M | 1.96M | 544.00K | 42.18M |
Total Liabilities | 62.99M | 49.87M | 51.66M | 198.32M | 167.44M | 23.50M |
Stockholders Equity | -34.37M | -25.89M | -25.94M | -176.33M | -129.60M | 228.52M |
Cash Flow | ||||||
Free Cash Flow | -35.51M | -41.19M | -51.17M | -33.10M | -23.95M | -1.22M |
Operating Cash Flow | -34.48M | -40.84M | -50.58M | -32.31M | -22.70M | -677.60K |
Investing Cash Flow | -993.00K | -345.00K | -2.12M | -1.79M | -2.26M | -250.00M |
Financing Cash Flow | 44.50M | 37.94M | 54.63M | 13.46M | 50.77M | 252.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$15.27B | 5.80 | -7.43% | 4.22% | 11.60% | -21.06% | |
55 Neutral | $366.95M | ― | -86.53% | ― | -7.84% | 42.34% | |
53 Neutral | $77.71M | ― | -35.68% | ― | 69.17% | 39.01% | |
53 Neutral | $168.43M | ― | -76.01% | ― | 25.62% | 11.86% | |
50 Neutral | $195.58M | ― | 271.41% | ― | 85.03% | 53.73% | |
48 Neutral | $152.26M | ― | -304.05% | ― | 28.24% | -334.39% | |
$137.91M | ― | ― | ― | ― |
On June 23, 2025, TriSalus Life Sciences announced the commencement of an exchange offer and consent solicitation for its Series A Convertible Preferred Stock. This initiative aims to streamline the company’s capital structure by allowing preferred shareholders to exchange their shares for common stock, thereby reducing potential dilution and improving transparency in equity value. Approximately 55% of preferred shareholders have agreed to the exchange and proposed amendments, which, if approved, will enable automatic conversion of remaining preferred shares into common stock. The offer is set to expire on July 23, 2025, and is contingent on certain conditions being met.
The most recent analyst rating on (TLSI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
On June 12, 2025, TriSalus Life Sciences, Inc. held its Annual Meeting of Shareholders, where 73.2% of the total outstanding shares were represented. During the meeting, two directors were elected for three-year terms, and the appointment of Grant Thornton, LLP as the independent registered accounting firm for 2025 was ratified.
The most recent analyst rating on (TLSI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
On May 30, 2025, TriSalus Life Sciences announced the appointment of David B. Patience as the new Chief Financial Officer, effective July 1, 2025, following the resignation of James E. Young for personal reasons. This leadership transition is expected to support the company’s growth phase, leveraging Patience’s extensive experience in financial leadership and market analysis, which could enhance TriSalus’s strategic positioning in the oncology sector.
The most recent analyst rating on (TLSI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
On April 30, 2025, TriSalus Life Sciences announced a securities purchase agreement to raise approximately $22 million through a private placement of common stock. This move is expected to fund the company to profitability and simplify its capital structure through an exchange offer for its Series A Convertible Preferred Stock. The company also reported preliminary Q1 2025 financial results, showing a 42% revenue growth compared to the previous year. The private placement, led by Nantahala Capital, involves healthcare-focused investors and aims to support the company’s strategic vision and operational growth.